State of Mexico Begins Purchasing Medical Marijuana, Inc.’s Products for its Citizens
August 22nd, 2017
News, Top News
Mexico’s War on Drugs has taken a tremendous toll over the years, but President Enrique Pena Nieto has learned from the past and is taking a new approach. The government has recently legalized medical marijuana in a landmark decisions and it’s now looking to purchase cannabinoid products to treat its citizens. These trends mark an important policy pivot and could yield opportunities for investors in the industry.
In this article, we will look at Mexico’s evolving drug policies and why investors may want to take a closer look at Medical Marijuana Inc. (OTC Pink: MJNA) as an opportunity in the space.
Liberalizing Drug Policy
Mexico’s War on Drugs has taken a tremendous toll on the country. Since the program began in late-2006, the death toll has exceeded 111,000, human rights violations have become a major concern, and drug use has dramatically increased along border states. Many drug cartels have also become involved with human trafficking, which represents a humanitarian crisis of its own spurred on by a largely unsuccessful war on drugs.
With several U.S. states legalizing marijuana, Mexico has started to take a different approach under President Enrique Pena Nieto. The country has even become a pioneer of medical cannabis by first permitting the importation of cannabidiol (“CBD”) oils and later legalizing medical cannabis on a broader level. Newly proposed measures would enable citizens to possess up to an ounce of cannabis without any repercussions.
“So far, the solutions [to control drugs and crime] implemented by the international community have been frankly insufficient,” said Pena Neito to the 2016 United Nations General Assembly Special Sessions in April 2016. “We must move beyond prohibition to effective prevention.”
The presidential decree effectively eliminates the criminalization of the medicinal use of cannabis THC, CBD, and all cannabis derivatives, while legalizing the production and distribution of cannabis for medicinal and therapeutic purposes. Moving forward, the Ministry of Health will be required to study the medical and therapeutic effects of the drug before creating a framework for a medical marijuana program.
Who’s Well Positioned?
There are few cannabis companies operating in Mexico and one clear leader in the space – Medical Marijuana Inc. (OTC Pink: MJNA).
In February 2016, the company became the first company to receive government import permits for cannabis products via approval by the Mexican Health Department, COFEPRIS. These permits were granted for individuals suffering from rare forms of epilepsy that may be effectively treated with cannabidiol (“CBD”) oils. The HempMeds Mexico products contain no psychoactive tetrahydrocannbinol (“THC”) and are 99% pure filtered CBD oil.
The company recently began clinical studies of its HempMeds RSHO-X products under the guidance of Dr. Saul Garza Morales, a leading pediatric researcher and neurologist in Mexico. The studies in children with severe epilepsy found that 86% of the 29 patients experienced statistically-significant (> 50%) reductions in motor seizures. A further 17% of the patients were fully seizure-free for a 4-month period following the clinical studies.
This week, the State of Mexico’s government announced that it would directly purchase CBD hemp oil products from HempMeds Mexico to treat 11 of its citizens suffering from varying indications, including Refractory Epilepsy and Lennox Gastaut-Syndrome. The move marks the first time that the government has purchased CBD products for its citizens, and successful results could translate to additional purchases down the road.
“The plethora of benefits of medical cannabis to treat several types of indications is undeniable and we are encouraged to see not only health professionals, but also now governments, are becoming increasingly interested in how CBD hemp oil can help heal,” said Medical Marijuana Inc. CEO Dr. Stuart Titus in a recent press release.
Medical Marijuana Inc. (OTC Pink: MJNA) represents a compelling opportunity to capitalize on Mexico’s liberalizing drug policies. With its scientific backing and government support, the company could leverage its success in Mexico across other countries where it has built up a sizable presence, including Brazil and other Latin American countries. Investors may want to keep an eye on the stock given these important catalysts.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.